



Rexahn Pharmaceuticals, Inc.  
Investor Relations Department  
15245 Shady Grove Road, Suite  
455  
Rockville, MD 20850  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

**AMEX: RNN**

Last Trade:	3.01
Trade Time:	4:02 PM ET 06/27/17
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.27 - 7.10
Volume	N/A

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- 06/07/17*  
[Rexahn Announces \\$10 Million Registered Direct Offering](#)
- 06/04/17*  
[Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology \(ASCO\) 2017 Annual Meeting](#)
- 05/08/17*  
[Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology \(ASCO\) 2017 Annual Meeting](#)
- 05/05/17*  
[Rexahn Effects 1-for-10 Reverse Stock Split](#)
- 05/04/17*  
[Rexahn Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update](#)

## Financials [\[ View all \]](#)

- [Fourth Quarter Financial Results](#)
- 02/24/17*  
[Annual Report \(10-K\)](#)
- 02/24/17*  
[Proxy Statement \(DEF 14A\)](#)
- 05/03/17*  
[Quarterly Report \(10-Q\)](#)
- 11/04/16*  
[Quarterly Report \(10-Q\)](#)
- 08/05/16*  
[Quarterly Report \(10-Q\)](#)